Biosimilars Overview

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

Oncobiologics has identified a pipeline of biosimilar candidates for further development.  The corresponding reference products for these candidates generated an aggregate of over $40 billion in global revenue in 2016.  The company’s most advanced assets, ONS-3010 (a biosimilar of Humira®) and ONS-1045 (a biosimilar of Avastin®) have both successfully completed Phase I trials. We are currently seeking partners to take these assets through Phase III trials.

We recently outlicensedthe remaining emerging markets rights to our most advanced clinical-stage product candidates, ONS-3010 and ONS-1045, and intend to rapidly commercialize these assets with our partner to begin generating revenue in 2020. We believe that this strategy will accelerate the development of our biosimilar pipeline and enhance market awareness of our biosimilar product candidates when we prepare to launch in developed markets. (See Product Pipeline)

We will continue to build our pipeline of early stage biosimilar product candidates for further development and commercialization. We believe that the long term value of our company will be driven by the launch of multiple biosimilar products from our pipeline.

We currently intend to enter into strategic collaborations and partnerships with biotechnology and pharmaceutical companies in the United States and other regions. We believe this strategy will allow us to maximize the impact of our financial resources and result in increased commercial value of our development programs.